Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery. “Patients with relapsed or refractory AML have poor outcomes, with response rates of between 30% and 40% to intensive salvage chemotherapy. Durable complete responses are even more uncommon,” Bradley W. Blaser, MD, PhD, assistant professor of leukemia research at The Ohio State University Comprehensive Cancer Center, told Healio. “Ficlatuzumab could
Denial of responsibility! TheTopMag.com is an automatic aggregator of all media around the world. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 72 hours.